Inside the new plan to end U.S. dependence on foreign drug ingredients — will it work this time?

The United States government will move to rapidly fill its Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) with domestically produced components for the nation’s most critical medicines, following an executive order signed by President Donald J. Trump on August 13, 2025. The order mandates a 30-day deadline to identify 26 high-priority drugs, secure funding, and begin procurement of active pharmaceutical ingredients (APIs) to strengthen the resilience of the American pharmaceutical supply chain.

The initiative marks a revival of Trump’s first-term push to onshore essential medicine manufacturing, a policy he claims stalled under the Biden administration despite significant federal spending on supply chain security. Only about 10% of APIs used in U.S. drug manufacturing are currently produced domestically, leaving the system heavily dependent on imports from foreign — and in some cases adversarial — nations.

Why is the United States prioritizing a strategic API reserve and what gap does it aim to close?

APIs are the biologically active components in finished drug products. While nearly two in five prescription finished drug products in the U.S. are manufactured domestically, the raw active ingredients that go into them are overwhelmingly sourced from overseas. The Trump administration created the SAPIR during his first term as a cost-effective safeguard — APIs generally cost less than finished medicines and have longer shelf lives, making them more practical for stockpiling.

By mandating the filling of the SAPIR, the administration aims to reduce exposure to geopolitical supply risks, particularly in the supply of key starting materials. Government purchases under the program are also expected to stimulate domestic API production capacity, which institutional observers say is vital to securing national health security.

How will the government select and secure APIs for the most critical medicines?

Within 30 days, the Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) will compile a list of approximately 26 drugs deemed most critical to U.S. health and security interests. This process will involve consultation with federal agencies holding relevant scientific expertise, along with the Assistant to the President for Economic Policy and the Assistant to the President and Homeland Security Advisor.

The executive order directs the ASPR to identify available funds and prepare the SAPIR repository to receive and store APIs within 120 days. Once certified as operational, the repository must be stocked with a six-month supply of APIs for the identified critical drugs within 30 days, prioritizing U.S.-manufactured APIs whenever possible.

What steps are being taken to expand and future-proof the API reserve?

The order also calls for an updated plan to maintain a six-month supply of APIs for all drugs on the government’s 2022 list of 86 essential medicines and medical countermeasures. This update must be delivered within 90 days and include a costed proposal for establishing a second SAPIR facility within one year, doubling the nation’s secure storage capacity.

Institutional stakeholders note that this expansion could help ensure the system’s resilience against both supply shocks and localized disruptions. By diversifying storage locations and increasing redundancy, the U.S. would be better positioned to respond to emergencies ranging from pandemics to geopolitical trade restrictions.

How does this directive differ from prior supply chain resilience efforts?

Trump’s order builds on the framework of Executive Order 13944 from August 2020, which first mandated increased domestic procurement of essential medicines and critical inputs. Analysts suggest the latest directive is more prescriptive and time-bound, introducing specific deadlines, measurable inventory targets, and a clear emphasis on domestic sourcing.

While previous administrations have identified vulnerabilities and invested in supply chain security, industry sentiment has often been that progress was slow, and results were mixed. By tying the initiative to a concrete inventory program, proponents believe the policy could translate into tangible preparedness gains, though execution risks remain.

What is the institutional and market sentiment toward the new pharmaceutical supply chain strategy?

Institutional observers view the move as a signal of policy continuity in Trump’s second term, reinforcing his administration’s broader reshoring agenda. Some healthcare supply chain executives see the API reserve as a critical insurance policy against future shortages, particularly for essential and emergency medicines. Others caution that building sustainable domestic API capacity will require not just government purchases but also private-sector investment and regulatory alignment.

From a market perspective, domestic API manufacturers could see increased demand in the near term, potentially benefiting firms with established compliance and production infrastructure. However, global pharmaceutical companies operating in the U.S. may face procurement adjustments, especially if federal contracts begin to favor U.S.-made APIs.

What are the potential outcomes and challenges of filling the strategic API reserve?

If fully executed as envisioned, the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) could mark a structural shift in how the United States safeguards its access to essential medicines. By holding a dedicated six-month buffer of APIs, the reserve would directly reduce the country’s dependence on high-risk foreign suppliers, particularly those in regions vulnerable to geopolitical instability or subject to export restrictions. This insulation from global supply shocks could also help mitigate the economic and health consequences of international trade disputes, manufacturing slowdowns, or shipping disruptions — scenarios that have previously triggered critical drug shortages in the U.S. healthcare system.

From a policy perspective, the six-month API supply target could set a new procurement benchmark, not only for federal agencies but also for state governments, hospital networks, and even private-sector buyers. Analysts suggest that if SAPIR’s inventory protocols are formalized into broader pharmaceutical procurement policy, it could influence how manufacturers structure contracts, manage production schedules, and diversify sourcing strategies. Over time, this could push the industry toward more localized or regionalized supply chains, with stronger redundancy built in as a matter of compliance and competitiveness.

Yet, the path to achieving these outcomes will require navigating significant operational challenges. Certain APIs — particularly those for complex biologics or niche therapies — have limited or no current domestic manufacturing capacity. Expanding this capability will demand substantial capital investment, technology transfer, and skilled workforce development. Beyond production, the government will need to ensure that storage and quality control systems at SAPIR repositories meet stringent Good Manufacturing Practice (GMP) standards, with robust protocols for monitoring shelf life, batch integrity, and temperature stability across multiple sites.

Funding sustainability is another critical factor. Stockpiling APIs at this scale involves recurring costs for procurement, testing, storage, and replenishment, and analysts warn that without secure, multi-year budget allocations, the reserve could suffer from under-maintenance. Institutional observers also emphasize the importance of transparent reporting on inventory levels, sourcing origins, and quality audits to maintain public trust and industry confidence. Without these safeguards — and without political will to keep the program prioritized over successive administrations — SAPIR risks joining the list of underutilized or dormant federal stockpile programs that failed to deliver their intended resilience benefits.